Cargando…
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depe...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553530/ https://www.ncbi.nlm.nih.gov/pubmed/33117602 http://dx.doi.org/10.1080/2162402X.2020.1818437 |
_version_ | 1783593622951690240 |
---|---|
author | Kaumaya, Pravin T. P. Guo, Linlin Overholser, Jay Penichet, Manuel L. Bekaii-Saab, Tanios |
author_facet | Kaumaya, Pravin T. P. Guo, Linlin Overholser, Jay Penichet, Manuel L. Bekaii-Saab, Tanios |
author_sort | Kaumaya, Pravin T. P. |
collection | PubMed |
description | Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depends on a combinatorial approach. Contrary to mAbs chimeric B-cell cancer vaccines incorporating a “promiscuous” T-cell epitope have the advantage of producing a polyclonal B-cell antibody that can potentially induce memory B- and T-cell responses, while reducing immune evasion and suppression. Here, we describe a novel PD-1 B-cell peptide epitope vaccine (amino acid 92–110; PD1-Vaxx) linked to a measles virus fusion peptide (MVF) amino acid 288–302 via a four amino acid residue (GPSL) emulsified in Montanide ISA 720VG that aims to induce the production of polyclonal antibodies that block PD-1 signaling and thus trigger anticancer effects similar to nivolumab. In preclinical studies, the PD1-Vaxx outperformed the standard anti-mouse PD-1 antibody (mAb 29F.1A12) in a mouse model of human HER-2 expressing colon carcinoma. Furthermore, the combination of PD1-Vaxx with combo HER-2 peptide vaccine (B-Vaxx) showed enhanced inhibition of tumor growth in colon carcinoma BALB/c model challenged with CT26/HER-2 cells. The PD-1 or combined vaccines were safe with no evidence of toxicity or autoimmunity. |
format | Online Article Text |
id | pubmed-7553530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-75535302020-10-27 Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model Kaumaya, Pravin T. P. Guo, Linlin Overholser, Jay Penichet, Manuel L. Bekaii-Saab, Tanios Oncoimmunology Original Research Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depends on a combinatorial approach. Contrary to mAbs chimeric B-cell cancer vaccines incorporating a “promiscuous” T-cell epitope have the advantage of producing a polyclonal B-cell antibody that can potentially induce memory B- and T-cell responses, while reducing immune evasion and suppression. Here, we describe a novel PD-1 B-cell peptide epitope vaccine (amino acid 92–110; PD1-Vaxx) linked to a measles virus fusion peptide (MVF) amino acid 288–302 via a four amino acid residue (GPSL) emulsified in Montanide ISA 720VG that aims to induce the production of polyclonal antibodies that block PD-1 signaling and thus trigger anticancer effects similar to nivolumab. In preclinical studies, the PD1-Vaxx outperformed the standard anti-mouse PD-1 antibody (mAb 29F.1A12) in a mouse model of human HER-2 expressing colon carcinoma. Furthermore, the combination of PD1-Vaxx with combo HER-2 peptide vaccine (B-Vaxx) showed enhanced inhibition of tumor growth in colon carcinoma BALB/c model challenged with CT26/HER-2 cells. The PD-1 or combined vaccines were safe with no evidence of toxicity or autoimmunity. Taylor & Francis 2020-10-01 /pmc/articles/PMC7553530/ /pubmed/33117602 http://dx.doi.org/10.1080/2162402X.2020.1818437 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Kaumaya, Pravin T. P. Guo, Linlin Overholser, Jay Penichet, Manuel L. Bekaii-Saab, Tanios Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model |
title | Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model |
title_full | Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model |
title_fullStr | Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model |
title_full_unstemmed | Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model |
title_short | Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model |
title_sort | immunogenicity and antitumor efficacy of a novel human pd-1 b-cell vaccine (pd1-vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like her-2 b-cell epitope vaccines (b-vaxx) in a syngeneic mouse model |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553530/ https://www.ncbi.nlm.nih.gov/pubmed/33117602 http://dx.doi.org/10.1080/2162402X.2020.1818437 |
work_keys_str_mv | AT kaumayapravintp immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel AT guolinlin immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel AT overholserjay immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel AT penichetmanuell immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel AT bekaiisaabtanios immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel |